Bromantane and LGD-4033 Interaction

Avoid
Mechanism-based 64% confidence

Bromantane and LGD-4033 have a potentially harmful interaction with 64% confidence. Both Bromantane and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.

Compound Profiles

Bromantane

Actoprotector | Dopamine Upregulation & Adaptive Energy

Bromantane's mechanism of action is fundamentally different from conventional stimulants and most nootropic compounds. Its primary action is the upregulation of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC) gene expression in the striatum and other dopaminergic brain regions.

Half-life: ~11 hours Typical dose: 50-100 mg/day cognitive
dopamine receptorgaba hepatotoxicteratogenic
View full profile

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Brain
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Bromantane, LGD-4033). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds share the teratogenic safety flag (Bromantane, LGD-4033). Monitor accordingly.

Frequently Asked Questions

Can I take Bromantane with LGD-4033?

Combining Bromantane with LGD-4033 is not recommended. Both Bromantane and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Bromantane and LGD-4033 safe together?

This combination carries significant risk. Both Bromantane and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Bromantane and LGD-4033?

Both Bromantane and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Bromantane and LGD-4033?

Bromantane has a half-life of ~11 hours and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Bromantane vs LGD-4033

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.